<div>Help Us Bring Relief to Those Suffering from Peripheral Neuropathy (read all the way through for comments on bottom)
</div>
<div><br />
</div>
<div>Peripheral neuropathy affects millions, causing chronic pain, numbness, and a diminished quality of life. Traditional treatments often fall short, leaving patients with limited options and ongoing suffering. WinSanTor, a pioneering biotech company, has developed a promising new treatment: WST-057, designed specifically to address the root causes of peripheral neuropathy and offer genuine relief.
</div>
<div><br />
</div>
<div>We are committed to seeking approval of our drug for all patients suffering from peripheral neuropathy. We are launching this GoFundMe campaign to establish an Expanded Access Program (EAP) for WST-057, providing access to this groundbreaking drug for patients who need it most but cannot wait for government agency approval and are ineligible for clinical trials. Your generous support will help us bring hope to those enduring the debilitating effects of peripheral neuropathy.
</div>
<div><br />
</div>
<div><strong>About WST-057:</strong>
</div>
<div>WST-057 is a novel therapeutic agent that targets the underlying mechanisms of peripheral neuropathy. Unlike current treatments that merely manage the symptom of pain only, WST-057 aims to repair and regenerate damaged nerves, offering the potential for long-term improvement and restored function.
</div>
<div><br />
</div>
<div>Key features of WST-057 include:
</div>
<ul>
<li><strong>Mechanism of Action: </strong>WST-057 works by stimulating nerve regeneration and repair, addressing the root cause of neuropathy.
</li>
<li><strong>Clinical Benefit: </strong>Early studies have shown significant improvement in nerve growth and improved function and reduction in neuropathy symptoms.
</li>
<li><strong>Safety Profile:</strong> The active ingredient in WST-057 is pirenzepine, an active ingredient that was previously approved in many countries (Germany, Austria, Japan, etc) outside the United States. It was selected as WinSanTor’s lead drug because of its historical systemic safety profile. WST-057 has demonstrated a favorable safety profile as a topical treatment, with minimal side effects reported in Phase 2 clinical trials.
</li>
</ul>
<div><br />
</div>
<div><strong>Our Mission:</strong>
</div>
<div><br />
</div>
<div>WinSanTor is committed to transforming the treatment landscape for peripheral neuropathy with some of the best research scientists in their respective fields. The company has received support and grants from the National Institutes of Health and Canadian Institutes of Health Research, private individuals, and strategic partners to start and continue our ongoing research and clinical trials. Because pirenzepine was approved historically in Europe but never approved in the United States, we anticipate approval in Europe before approval in the United States. Therefore, the EAP aims to provide WST-057 to patients in the USA, who are unable to participate in the clinical trial before the drug receives market approval.
</div>
<div><br />
</div>
<div><strong>How Your Donation Will Be Used:</strong>
</div>
<div><br />
</div>
<div>Every dollar raised by the GoFundMe campaign will directly support the launch of the EAP including:
</div>
<ul>
<li><strong>Program Set-Up Costs:</strong> Infrastructure and resources will be appropriated to support this program and Patient Portal created to facilitate patient interactions.
</li>
<li><strong>FDA Submission:</strong> Submit the required documents to the FDA as per regulations to initiate the program.
</li>
<li><strong>Medical Oversight:</strong> WinSanTor needs a network of doctors in each state distributing WST-057 to monitor patient safety.
</li>
<li><strong>Program Administration:</strong> Management of the logistics and operations of the program to ensure seamless access for those in need.
</li>
</ul>
<div><br />
</div>
<div><strong>Impact of Your Support:</strong>
</div>
<div><br />
</div>
<div>Drug development is expensive (by some estimates over $2B/drug). By funding this initiative, you help WinSanTor initiate this EAP, which otherwise we couldn’t do, that will make available WST-057 at our direct cost to hundreds of patients in desperate need of a new therapeutic approach.
</div>
<div><br />
</div>
<div><strong>Join Us in Making a Difference:</strong>
</div>
<div><br />
</div>
<div>We invite you to be part of this life-changing mission. Donate today to our GoFundMe campaign and help us bring WST-057 to those who need it most. Every contribution, no matter the size, moves us closer to our goal of ending the suffering caused by peripheral neuropathy.
</div>
<div><br />
</div>
<div><strong>Thank You for Your Support!</strong>
</div>
<div><br />
</div>
<div>For more information about WinSanTor and our mission, please visit WinSanTor.com. Together, we can create a future where healing and hope are within reach for everyone affected by peripheral neuropathy.
</div>
<div><br />
</div>
<div>______________________________________________________
</div>
<div><br />
</div>
<div><strong>Donation Tiers:</strong>
</div>
<div><br />
</div>
<div><strong>All donations are welcome. Below is an example of what each amount can help achieve. We thank you for your support in helping friends, family, and others.</strong>
</div>
<ul>
<li><strong>$50:</strong> Provides instructional support and materials for one patient.
</li>
<li><strong>$100: </strong>Covers the cost of a single participant baseline interview
</li>
<li><strong>$500: </strong>Funds the Patient Portal Web Hosting for 4 patients
</li>
<li><strong>$1,000: </strong>Funds the medical monitoring review network for 1 day
</li>
<li><strong>5,000: </strong>Funds the storage depot for the WST-057 for one month
</li>
<li><strong>10,000: </strong>Covers the fees necessary to translate one patient reported outcome measure
</li>
<li><strong>25,000: </strong>Funds the clinical trial protocol submission to the FDA
</li>
</ul>
<div>Support the EAP for WST-057 and share this opportunity with your friends and family.
</div>
<div><br />
</div>
<div><strong>Why WinSanTor Needs Your Help to Fund the Expanded Access Program</strong>
</div>
<div><br />
</div>
<div>WinSanTor is deeply committed to developing innovative treatments for peripheral neuropathy, with WST-057 standing as a testament to our dedication and scientific breakthroughs. However, as a small biotech company, we face significant financial constraints that limit our ability to fund expensive programs independently.
</div>
<div><br />
</div>
<div>Here are the key reasons why WinSanTor is launching this campaign to finance the EAP for WST-057:
</div>
<div>1.	High Research and Development Costs: Developing a new drug involves extensive research, clinical trials, and regulatory processes, all of which are incredibly costly. All of our financial resources are allocated to these critical areas to ensure that WST-057 meets the stringent standards required for approval and widespread use.
</div>
<div>2.	Unprecedented Path Forward: Our novel therapy is a breakthrough for people living with DPN and novel science requires significant capital.. WinSanTor is a true pioneer in paving a path forward in all aspects and we’ve accomplished so much with continued support from the industry, investors, and especially from people like you.
</div>
<div>3.	Limited Funding: Unlike large pharmaceutical companies, we operate with a constrained budget primarily sourced from partnerships and grants. These funds are earmarked for specific phases of drug development, leaving limited room for additional initiatives such as the EAP. The funding from GoFundMe helps kickstart this program to help as many people as we can.
</div>
<div>4.	Regulatory and Compliance Expenses: Ensuring that WST-057 complies with all regulatory requirements for the EAP involves additional unbudgeted expenses. This includes extensive documentation, audits, and ongoing oversight, all necessary to bring a new drug to market safely and effectively.
</div>
<div>5.	Manufacturing and Distribution Costs: Producing and distributing WST-057, particularly on a scale that could support an EAP includes additional raw materials, production facilities, quality control, and logistics, all of which are financially demanding.
</div>
<div>6.	Sustaining Core Operations: As a growing biotech firm, maintaining our core operations, including paying our talented team, sustaining our research facilities, and continuing our pipeline of innovative treatments, requires a steady flow of funds. Diverting resources to an EAP without external support could jeopardize our primary mission.
</div>
<div>7.	Focus on Long-Term Solutions: The GoFundMe campaign will help patients immediately through an EAP while not disrupting our primary goal of achieving full regulatory approval for WST-0-57, leading to long-term sustainability and broader impact.
</div>
<div><br />
</div>
<div>By contributing to our GoFundMe campaign, you enable us to bring hope sooner to those suffering from peripheral neuropathy who cannot wait for full approval in the United States. Your support is crucial in helping us extend the benefits of WST-057 to patients who need it most, while we continue working towards broader accessibility and regulatory approval.
</div>
<div><br />
</div>
<div>Together, we can make a profound difference in the lives of those enduring the limitations of peripheral neuropathy. Thank you for your understanding, compassion, and generosity.
</div>
<div><br />
</div>
<div>Thisi is a legitimate request from WinSanTor (you can email us). WinSanTor is a small biotech company (&lt;10 people) advancing a disease overlooked and neglected by industry, investors and for many here, the healthcare system. We've had to push forward with grants and partnerships, and had to "prove" everything, including that this is a real market and disease. We created this GoFundMe to prove that there is a demand, and a need. We need your help to show this. Please donate and send this to everyone you know. Here is a recent article with more information - <a href="https://www.vcpost.com/articles/128243/20240728/restoring-hope-winsantors-innovative-approach-to-peripheral-neuropathy.htm" target="_blank" rel="noreferrer noopener"><a href="https://www.vcpost.com/articles/128243/20240728/restoring-hope-winsantors-innovative-approach-to-peripheral-neuropathy.htm" target="_blank" class="" rel="nofollow noopener noreferrer">https://www.vcpost.com/articles/128243/20240728/restoring-hope-winsantors-innovative-approach-to-peripheral-neuropathy.htm</a></a>
</div>
<div>Thank you.
</div>
<div>Stanley Kim
</div>

joe hester

Kieran O’Gorman

Anonymous

JEFFREY BROWN

Kateri Tyre

Mary Korman

Tommy Wong

paul marren

Paul Gaskins

Arian Hagen

Jeff Guthrie

Sarah Burnett

Jeffrey Adik

Randal Cooper

john binkley

Donate to Bring Relief to Peripheral Neuropathy Patients

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Donate to Bring Relief to Peripheral Neuropathy Patients

Still $148,165 to go. Help us build momentum.